Androstenedione, or 4-androstenedione, also known as androst-4-ene-3,17-dione, is an endogenous weak androgen steroid hormone and intermediate in the biosynthesis of estrone and of testosterone from dehydroepiandrosterone (DHEA). It is closely related to androstenediol (androst-5-ene-3β,17β-diol).
Methyltestosterone, sold under the brand names Android, Metandren, and Testred among others, is an androgen and anabolic steroid (AAS) medication which is used in the treatment of low testosterone levels in men, delayed puberty in boys, at low doses as a component of menopausal hormone therapy for menopausal symptoms like hot flashes, osteoporosis, and low sexual desire in women, and to treat breast cancer in women. It is taken by mouth.
Sustanon is a trade name owned by Organon Pharmaceuticals for oil-based injectable blends of esterified testosterone compounds.
Goserelin, sold under the brand name Zoladex among others, is a medication which is used to suppress production of the sex hormones, particularly in the treatment of breast and prostate cancer. It is an injectable gonadotropin releasing hormone agonist.
Leuprorelin, also known as leuprolide, is a manufactured version of a hormone used to treat prostate cancer, breast cancer, endometriosis, uterine fibroids, and early puberty. It is given by injection into a muscle or under the skin.
Nandrolone decanoate, sold under the brand name Deca-Durabolin among others, is an androgen and anabolic steroid (AAS) medication which is used primarily in the treatment of anemias and wasting syndromes, as well as osteoporosis in menopausal women. It is given by injection into muscle once every one to four weeks.
Gestonorone caproate, also known as gestronol hexanoate or norhydroxyprogesterone caproate and sold under the brand names Depostat and Primostat, is a progestin medication which is used in the treatment of enlarged prostate, endometrial cancer, and breast cancer. It is not effective by mouth and must be given by injection into muscle, typically once a week.
Androgen replacement therapy (ART), often referred to as testosterone replacement therapy (TRT), is a form of hormone therapy in which androgens, often testosterone, are replaced. ART is often prescribed to counter the effects of male hypogonadism. It typically involves the administration of testosterone through injections, skin creams, patches, gels, or subcutaneous pellets.
Transgender hormone therapy of the female-to-male (FTM) type, also known as masculinizing hormone therapy, is a form of hormone therapy and sex reassignment therapy which is used to change the secondary sexual characteristics of transgender people from feminine to masculine. It is one of two types of transgender hormone therapy, and is predominantly used to treat transgender men and other transmasculine individuals. Some intersex people also receive this form of therapy, either starting in childhood to confirm the assigned sex or later if the assignment proves to be incorrect.
Testosterone undecanoate, sold under the brand names Nebido, Aveed, and Andriol among others, is an androgen and anabolic steroid (AAS) medication which is used mainly in the treatment of low testosterone levels in men. It is also used in hormone therapy for transgender men. It is taken by mouth two to three times per day with food or given by injection into muscle once every 12 weeks or so.
Estradiol undecylate (EU), also known as estradiol undecanoate and formerly sold under the brand names Delestrec and Progynon Depot 100 among others, is an estrogen medication which has been used in the treatment of prostate cancer in men. It has also been used as a part of hormone therapy for transgender women. Although estradiol undecylate has been used in the past, it was discontinued and hence is no longer available. The medication has been given by injection into muscle usually once a month.
Hydroxyprogesterone heptanoate (OHPH), sold under the brand names H.O.P., Lutogil A.P., and Lutogyl A.P. among others, is a progestin medication which was developed by Roussel and Théramex and has been used clinically in France and Monaco but is no longer marketed. It was a component of the experimental preparation Trophoboline, which also contained nandrolone decanoate and estrapronicate. The medication was also studied or used in Tocogestan, a combination of hydroxyprogesterone heptanoate (200 mg), progesterone (50 mg), and tocopherol (250 mg) oil for intramuscular injection. OHPH has been marketed since at least 1957, in combination preparations such as Triormon Depositum and Trioestrine Retard.
Cloxotestosterone acetate, also known as testosterone 17β-chloral hemiacetal O-acetate, is a synthetic, injected anabolic–androgenic steroid (AAS) and an androgen ether and ester – specifically, the O-acetate ester of cloxotestosterone, the 17β-trichloro hemiacetal ether of testosterone. It is administered via intramuscular injection as a 100 mg, 2 mL aqueous suspension and lasts 4 to 6 weeks with a single administration. The drug was first marketed in the early 1960s.
Climacteron is a combination formulation of 1.0 mg estradiol benzoate, 7.5 mg estradiol dienanthate, and 150 mg testosterone enanthate benzilic acid hydrazone which is used in the treatment of menopausal symptoms in postmenopausal women. It is administered by intramuscular injection and is given once every 4 to 8 weeks or less frequently.
Omnadren is an oil-based mixture of testosterone esters for depot intramuscular injection that is no longer marketed. Its constituents included:
GTx-758 is a synthetic nonsteroidal estrogen which is under development by GTx, Inc. for the treatment of advanced prostate cancer. As of 2016, it has completed two phase II clinical trials.
Deposterona is an oil-based mixture of testosterone esters for depot intramuscular injection that is marketed in Mexico and is used in veterinary medicine. Its constituents include:
Prasterone enanthate is a synthetic, injected, long-lasting ester prodrug of dehydroepiandrosterone (DHEA), a weak androgen and neurosteroid. It is a component of Gynodian Depot, a combination formulation of 4 mg estradiol valerate and 200 mg prasterone enanthate in oil for depot intramuscular injection typically once every 4 weeks, that is used in the treatment of menopausal symptoms and is marketed in Europe and South America. Prasterone enanthate has an average duration of 18 days in this formulation. The pharmacokinetics of the formulation have also been assessed in other studies. The medication was patented, by Schering, in 1971.
Polyestriol phosphate, sold under the brand names Gynäsan, Klimadurin, and Triodurin, is an estrogen medication which was previously used in menopausal hormone therapy in Germany but is now no longer available. Its effects on the vagina, uterus, pregnancy, prostate gland, coagulation, and fibrinolysis, as well as on mammary and endometrial cancer risk, have been studied. PE3P has been used at dosages of 40 to 80 mg per month by intramuscular injection. A single 50 mg injection of PE3P has a duration of approximately one month and a single 80 mg injection has a duration of approximately two months. PE3P is similar to polyestradiol phosphate and is, likewise, an estrogen ester – specifically, an ester and prodrug of estriol – in the form of a polymer with phosphate linkers. It contains about 80% estriol. The medication was developed and marketed by the Swedish pharmaceutical company Leo Läkemedel AB.
